Gerresheimer earns EcoVadis score of 82. Gerresheimer stock sits 3.49 percent below its 52-week high

Published on 10/22/2026 at 09:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gerresheimer scored 82 out of 100 and ranked in the top 5 percent. Gerresheimer stock costs EUR 32.12 on October 22, 2026, 3.49 percent below its high.

Rating, target and market price

Gerresheimer lifted its EcoVadis score to 82 on October 14, 2026.
LBBW raised its target from EUR 28.00 to EUR 29.00 on October 6, 2026.
Gerresheimer stock trades at EUR 32.12 at 9:46 a.m. CEST at Lang & Schwarz on October 22, 2026, 0.12 percent above the Xetra close of October 21, 2026.

Bauhaus-Poster mit geometrischen Glasfläschchen und Schriftzug PHARMA — Gerresheimer AG, ISIN DE000A0LD6E6, inspiriert dieses geometrische Bauhaus-Poster mit stilisierten Glasfläschchen und dem Wort PHARMA, Illustration mit AI erstellt.

Gerresheimer (ISIN DE000A0LD6E6) raised its EcoVadis sustainability score to 82 out of 100 on October 14, 2026, placing the packaging and drug-delivery group among the top 5 percent of rated companies, according to MarketScreener. Gerresheimer stock was trading at EUR 32.12 at 9:46 a.m. CEST on October 22, 2026, or EUR 0.04 above the Xetra close of October 21, 2026.

Rating improvement meets a fragile recovery

The EcoVadis score rose from 78 in 2025 to 82 in 2026. Gerresheimer ranked in the top 2 percent of its industry and in the top 1 percent for sustainable procurement, giving the corporate announcement a measurable operating context.

The market backdrop remains more demanding. The stock price was EUR 32.12 on October 22, 2026, while the 52-week range stood at EUR 14.83 to EUR 33.28, leaving the quotation 3.49 percent below its high.

What does the 82-point rating add?

The rating does not change the immediate financial test: preliminary second-quarter 2026 revenue was EUR 578 million, down from EUR 614 million in the second quarter of 2025, while adjusted EBITDA was EUR 102 million versus EUR 126 million, according to Goldesel. Sequentially, adjusted EBITDA increased by EUR 35 million from the first quarter of 2026, and the adjusted EBITDA margin reached 17.6 percent.

Three transactions shape the recovery

On July 29, 2026, Gerresheimer agreed to sell Centor and Primary Packaging Plastics at a combined enterprise value of EUR 1.5 billion. On September 30, 2026, the company reported second-quarter adjusted EBITDA of EUR 102 million, up more than 50 percent from the first quarter. On October 14, 2026, the EcoVadis score reached 82, the latest of the three dated developments.

Which dates come next?

Gerresheimer is scheduled to report third-quarter 2026 results on October 31, 2026, while the investor calendar lists a quarterly statement for December 2026, according to Gerresheimer. The dates will test whether the expected stronger second half can offset the first-half revenue decline to EUR 1.10 billion from EUR 1.14 billion a year earlier.

Target remains below the quotation

On October 6, 2026, LBBW raised its price target from EUR 28.00 to EUR 29.00 and retained a Hold rating, as reported by Goldesel. That target is EUR 3.12 below the Lang & Schwarz quotation, while the Centor proceeds are intended for debt reduction and the Primary Packaging Plastics disposal is expected in the first half of 2027.

Stock stays near its yearly high

Gerresheimer operates in healthcare packaging and drug-delivery systems, with its shares listed on Xetra and included in the MDAX. The valuation signal is mixed: the share price remains 3.49 percent below its 52-week high, while the latest target increase still stops below the market quotation.

Gerresheimer was trading at EUR 32.12 at Lang & Schwarz on October 22, 2026 at 9:46 a.m. CEST, 0.12 percent above the Xetra close of October 21, 2026 at EUR 32.08. The further course of trading is shown by the continuously updated real-time quote of Gerresheimer stock.